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Mutations in C12orf65
in Patients with Encephalomyopathy
and a Mitochondrial Translation Defect
Hana Antonicka,1,7 Elsebet Østergaard,2,7 Florin Sasarman,1 Woranontee Weraarpachai,1
Flemming Wibrand,2 Anne Marie B. Pedersen,3 Richard J. Rodenburg,4 Marjo S. van der Knaap,5
Jan A.M. Smeitink,4 Zoﬁa M. Chrzanowska-Lightowlers,6 and Eric A. Shoubridge1,*
We investigated the genetic basis for a global and uniform decrease inmitochondrial translation in ﬁbroblasts from patients in two unre-
lated pedigrees who developed Leigh syndrome, optic atrophy, and ophthalmoplegia. Analysis of the assembly of the oxidative phos-
phorylation complexes showed severe decreases of complexes I, IV, and V and a smaller decrease in complex III. The steady-state levels
of mitochondrial mRNAs, tRNAs, and rRNAs were not reduced, nor were those of themitochondrial translation elongation factors or the
protein components of the mitochondrial ribosome. Using homozygosity mapping, we identiﬁed a 1 bp deletion in C12orf65 in one
patient, and DNA sequence analysis showed a different 1 bp deletion in the second patient. Both mutations predict the same premature
stop codon. C12orf65 belongs to a family of four mitochondrial class I peptide release factors, which also includes mtRF1a, mtRF1, and
Ict1, all characterized by the presence of a GGQ motif at the active site. However, C12orf65 does not exhibit peptidyl-tRNA hydrolase
activity in an in vitro assay with bacterial ribosomes. We suggest that it might play a role in recycling abortive peptidyl-tRNA species,
released from the ribosome during the elongation phase of translation.Combined deﬁciencies in the enzyme complexes of
the oxidative phosphorylation (OXPHOS) system are a
common cause of mitochondrial disease. They are
associated with a wide variety of distinct clinical pheno-
types and can be caused by mutations in either the
mitochondrial (mtDNA) or nuclear genome. Mutations
in mitochondrial tRNAs and rRNAs, as well as large-scale
mtDNA deletions, have been known for over 20 years,1
and several gene defects, many of which are implicated
in mitochondrial translation, have been identiﬁed in
patients with autosomal recessive combined OXPHOS
deﬁciencies (reviewed in 2).
The synthesis of the 13 mtDNA-encoded OXPHOS
subunits is carried out on dedicated mitochondrial ribo-
somes with translation machinery that resembles that of
prokaryotes; however, the regulation of this system is
poorly understood. Although the basic components
required for initiation, elongation, and termination of
mitochondrial translation have been identiﬁed and
cloned,3 much of our knowledge has been inferred from
prokaryotic systems, and it is clear that many essential
components of mammalian mitochondrial translation
remain to be discovered.4 The precise roles of all the
proteins involved in translation termination are particu-
larly unclear.5
During the termination of protein synthesis, translation
termination (release) factors catalyze the release of the
nascent polypeptide chain when a stop codon on the1Montreal Neurological Institute and Department of Human Genetics, McGil
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The Atranslated mRNA appears in the A site of the ribosome.
In prokaryotes, four proteins are involved in translation
termination: two class I release factors, RF1 and RF2, which
recognize the three stop codons present in prokaryotes
(UAA, UAG, and UGA) and facilitate hydrolysis of the ester
bond between the tRNA and nascent polypeptide in the
peptidyl transferase center of the ribosome; RF3, a class II
release factor with GTPase activity that stimulates the
removal of RF1 and RF2 from the ribosome after the release
of the polypeptide chain; and RRF, ribosomal recycling
factor, which is essential for the release of ribosomes
from mRNA (reviewed in 6).
The mitochondrial translation machinery utilizes
a modiﬁed set of codons in which the conventional stop
codon UGA has been transformed to code for tryptophan.
In vertebrate mitochondria, only two stop codons (UAG
and UAA) are used for termination, and these are recog-
nized by a single class I release factor mtRF1a/mtRF1L, as
demonstrated by in vitro translation termination assays
that use E. coli 70S ribosomes and by in vivo restoration
of respiratory deﬁciency resulting from deletion of the
endogenous mitochondrial RF in yeast.7–9 Two ribosome
recycling factors, mtRRF10,11 and mtRRF2 (EFG2), have
also been described,12 but no class II release factor has
been identiﬁed in mitochondria.
All known class I release factors have a GGQmotif at the
active site of the protein that catalyzes the hydrolysis of
the ester bond, but there are no clear sequence similaritiesl University, Montreal H3A 2B4, Quebec, Canada; 2Department of Clinical
Denmark; 3Department of Pediatrics, Glostrup Hospital, Glostrup 2600,
iatrics, Radboud University Nijmegen Medical Centre, Nijmegen 6500 HB,
Amsterdam 1081 HV, The Netherlands; 6Mitochondrial Research Group,
stle upon Tyne NE2 4HH, UK
Genetics. All rights reserved.
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Figure 1. Characterization of the Molec-
ular Defect in Patients with a Decrease in
Mitochondrial Translation and Rescue of
the Biochemical Phenotype by Expression
of C12orf65
(A and B) Control and patient ﬁbroblasts
both alone and overexpressing C12orf65
were analyzed by BN-PAGE (A) and by
pulse labeling of mitochondrial polypep-
tides (B). In (A), each of the ﬁve OXPHOS
complexes (I–V) was visualized with
a subunit-speciﬁc antibody. In (B), the
seven subunits of complex I (ND), one
subunit of complex III (cyt b), three
subunits of complex IV (COX), and two
subunits of complex V (ATP) are indicated
at the left of the ﬁgure.
(C) Control and patient ﬁbroblasts were
analyzed by immunoblotting with anti-
bodies against mitochondrial translation
elongation factors (EFG1, EFTu, and EFTs)
and mitochondrial ribosomal proteins
(MRPL13, MRPL15, MRPL32 [a kind gift
of T. Langer], and MRPS2 [a kind gift of L.
Spremulli, UNC Chapel Hill]). The 70 kDa
subunit of complex II was used as a loading
control.at the stop codon recognition site. Based on this sequence
homology, three additional putative mitochondrial class I
release family members containing the GGQ motif can
be identiﬁed: mtRF1, Ict1, and C12orf65.5 Ict1 has recently
been shown to be an integral component of the large mito-
chondrial ribosomal subunit (mt-LSU) and to possess ribo-
some-dependent but codon-independent peptidyl-tRNA
hydrolase activity.5 Human Ict1 is 29% identical to the
bacterial protein YaeJ, which is thought to mediate stop
codon independent polypeptide release activity from
stalled 50S ribosomes, in which the unﬁnished protein
remains threaded through the exit tunnel, suggesting
that Ict1 might have a similar function.5,13 The precise
functions of mtRF1 and C12orf65 remain unknown.
Herewe have investigated patients in two unrelated pedi-
grees with combined OXPHOS deﬁciencies associated with
a decrease in the synthesis of all mitochondrially encoded
polypeptides. Informed consent was obtained and research
studies were approved by the Helsinki Committee of the116 The American Journal of Human Genetics 87, 115–122, July 9, 2010Radboud University Nijmegen Medi-
calCentre and theMontrealNeurolog-
ical Institute Institutional Review
Boards.
Patient 1, a girl, was the third child
born to healthy ﬁrst-cousin parents of
Turkish descent. The two older
siblings were healthy. Birth weight
was 3300 g, birth length was 51 cm.
Pregnancy, birth, and the ﬁrst year
of life were unremarkable. From age
1, the patient had failure to thrive
with swallowing problems and regres-sion of psychomotor development. At 18 months, psycho-
motor retardation, ataxia, and ptosis were found. An
ophthalmological examination showed bilateral paresis
of N. abducens. At age 3 years, nystagmus was found,
and at age 5 years, severe optic atrophy and decreased
vision were found. A cerebral MRI at age 2 years showed
bilateral lesions in the thalami, brain stem, and medulla
spinalis, and a diagnosis of Leigh syndrome (MIM
#256000) was made. At 8 years, her height and weight
were normal for her age. She was hypermobile with ataxia
and used a wheelchair. She had severely reduced vision
with optic atrophy and ophthalmoplegia. Plasma lactate
was on one occasion elevated to 2.7 mmol/l. Urine organic
acids, urine amino acids, and plasma amino acids were
normal. The patient died at age 8.
Patient 2, a boy, was a second child of healthy unrelated
Dutch parents. His older brother was also affected. Preg-
nancy and delivery were uneventful. His initial develop-
ment was normal. At 15months, he developed nystagmus.
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Figure 2. Normal Levels of Mitochondrial mRNAs, rRNAs, and tRNAs in Patient Fibroblasts
(A) RNA blot analysis was carried out with total RNA extracted from control and patient ﬁbroblasts. Hybridization was performed with
probes speciﬁc for the mitochondrial mRNAs encoding the three COX subunits, two of the complex I subunits (ND), 12S and 16S mito-
chondrial ribosomal RNA, and, as a loading control, a probe for beta-actin.
(B) Quantiﬁcation of mitochondrial mRNA and rRNA levels in ﬁbroblasts normalized to actin levels.
(C) Total RNA was extracted from control and patient cells, and 5 mg of RNA was run on a 10% polyacrylamide gel containing 7 M urea.
After transfer to membrane, hybridization was performed with oligonucleotide probes complementary to the mitochondrial tRNAs for
Lys, Glu, Gln, Trp, and Val, and, as a loading control, the cytosolic tRNA for Glu (cyt Glu), as indicated at the right of the ﬁgure.
(D) Quantiﬁcation of mitochondrial tRNA levels in patient 1 ﬁbroblasts, normalized to levels of cytosolic tRNA for Glu.MRI of the brain was normal at age 2. From the age of
3–4 years, slow deterioration of motor and cognitive func-
tion occurred. At the age of 8 years, he became wheelchair
dependent. Electromyogram at 8 years of age showed signs
of an axonalneuropathy.At ages 14 and17, hehad episodes
of paralytic ileus. At age 14, he developed a respiratory
insufﬁciency and from then on remained dependent on
ventilatory support. He also received a percutaneous gastro-
stomy tube.Neurological examination at the age of 20 years
revealed optic atrophywith diminished vision. A divergent
squint, irregular nystagmus, and incomplete external oph-
thalmoplegia with limited eye movements in all directions
were present. There were signs of bulbar paresis with nega-
tive masseter reﬂex, facial diplegia, difﬁculty chewing and
swallowing, and a mild dysarthria. Examination of the
arms and legs revealed global muscle atrophy and hypo-
tonia. The deep tendon reﬂexes were negative. There was
a paresis of the proximal muscles and a paralysis of distal
muscles, accompanied by distal decrease of sensory func-
tions, consistent with a polyneuropathy.The AAn older brother of patient 2 presented with similar
development. Pregnancy, delivery, and initial development
were normal. Nystagmus was noted at birth. At age 3 years,
a divergent squint arose. Ophthalmological examination
revealed optic atrophy. MRI of the brain was normal at
that time. From the age of 7 years, slow deterioration of
vision and motor and cognitive function occurred. He
also developed urinary stress incontinence. Neurological
examination at the age of 21 years revealed optic atrophy
with diminished vision, divergent squint, irregular
nystagmus, incomplete external ophthalmoplegia with
limited eye movements, and bulbar paresis. Examination
of the arms and legs revealed atrophy and weakness of the
distalmuscles, aswell as distal decrease in sensory function.
Therewere no evident signs of a cerebellar ataxia. At the age
of 22 years, he developed a respiratory tract infection, respi-
ratory insufﬁciency, and paralytic ileus.MRI of the brain re-
vealed extensive signal abnormalities in the brain stem,
especially the midbrain and medulla, with restricted diffu-
sionandenhancement after contrast. Therewere also signalmerican Journal of Human Genetics 87, 115–122, July 9, 2010 117
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Figure 3. Mutational Analysis of
C12orf65 and Mitochondrial Localization
of the Protein
(A) Schematic diagram of the C12orf65
gene and protein. The position of the
mutation in the patient DNA and the posi-
tion of the resulting premature stop codon
are indicated. Dark boxes in the C12orf65
gene denote the coding regions; gray
boxes denote 50UTRs and 30UTRs. The
white box in C12orf65 protein indicates
the predicted mitochondrial leader
sequence.
(B) Sequencing analysis of C12orf65 cDNA
indicating the position of the homozygous
248delT and 210delA mutations in patient
1 and patient 2, respectively.
(C) Control ﬁbroblasts expressing
c12orf65-FLAG were grown on coverslips
and incubated with antibodies against
FLAG and against cytochrome c, as indi-
cated, followed by incubation with
secondary antibodies coupled to red and
green ﬂuorescent dyes. Merging the two
images demonstrates the mitochondrial
localization of C12orf65.abnormalities in the cerebellar white matter and thalamus.
Magnetic resonance spectroscopy of the brain stem re-
vealed highly elevated lactate. He died a few months later.
The disease progression in all of these patients is much
slower than that seen in patients with classical Leigh
syndrome, caused by, for instance, SURF1 (MIM 185620)
mutations,14 which is usually fatal in the ﬁrst few years
of life, but it is reminiscent of patients with mutations in
the recently described mitochondrial translation activator
TACO1.4
Primary cultured human skin ﬁbroblasts obtained from
patient biopsies were immortalized with a retrovirus
expressing the E7 gene of type 16 human papilloma virus
and a retroviral vector expressing the protein component
(htert) of human telomerase.15 Control ﬁbroblast lines
were obtained from the cell bank of the Montreal Chil-
dren’s Hospital, and at least two such lines were used
in each experiment. Patient 1 was shown to have decreased
cytochrome c oxidase (COX, complex IV) activity in ﬁbro-
blasts (COX/citrate synthase 0.27 versus control mean
0.68, control range 0.4–1.1),14 and BN-PAGE analysis16,17
revealed severe assembly defects in complexes I, IV, and
V, with a milder defect in the assembly of complex III118 The American Journal of Human Genetics 87, 115–122, July 9, 2010(Figure 1A). Subcomplexes could not
be detected by this analysis with anti-
bodies directed against subunits of
complex I or complex IV. Synthesis
of the mtDNA-encoded polypep-
tides18 was also severely and
uniformly affected (~30% of control
levels; Figure 1B). This pattern of
mitochondrial translation deﬁciency
is distinct from that found in othergenetically deﬁned patients with mitochondrial transla-
tion defects in whom speciﬁc decreases in the synthesis
of individual polypeptides have been reported.19,20 The
levels of all tested mitochondrial transcripts, rRNAs, and
tRNAs were unchanged or were higher when compared
to controls (Figure 2). Western blot analysis, carried out
on ﬁbroblasts solubilized in 1.5% lauryl maltoside with
10–20 mg of protein, showed normal levels of mitochon-
drial ribosomal subunits, as well as mitochondrial transla-
tion elongation factors (Figure 1C), suggesting that the
translation defect was not due to an impaired assembly
of the mitochondrial ribosome.
DNA extracted from peripheral blood was used for
a genome-wide search for homozygosity with the Affyme-
trix GeneChip 50K Xba array. The SNP analysis showed
a large number of homozygous regions, altogether
comprising around 200 Mb and containing 1473 genes
(see Table S1 available online). In order to prioritize candi-
date genes, we used the Maestro database to identify genes
with a signiﬁcant score (>4.0) for encoding amitochondrial
protein.21 The database search identiﬁed 69 genes with
a score of over 4. Two of the genes, EFG1 (MIM 606639)
and MRPS22 (MIM 605810), encode proteins that are part
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Figure 4. Knockdown of Ict1 in Control Fibroblasts Results in a Mitochondrial Translation Defect Similar to that in Patients with
C12orf65 Mutations
(A and B) Control ﬁbroblasts were transiently transfected with small interfering RNA constructs speciﬁc to Ict1 and analyzed by BN-PAGE
(A) and [35S] Met/Cys-labeling (B) of mitochondrial polypeptides.
(C) Control ﬁbroblasts that were untreated, overexpressing, or depleted for Ict1 were analyzed by immunoblotting for the presence of
mitochondrial ribosomal proteins (DAP3 and MRPL32). A patient with a mitochondrial ribosome assembly defect (Comb. def. patient)
was used as a positive control.of the mitochondrial translation machinery, but no muta-
tions were found by sequence analysis. Sequence analysis
of cDNA and genomic DNA from C12orf65, a putative class
I release factor, revealed a homozygous 1 bp deletion
(248delT), which resulted in a premature stop codon
(Figures 3A and 3B). Although we cannot rule out hemi-
zygosity in this patient, both parents (and an older sister)
were heterozygous carriers of the mutation, making it
unlikely. An older brother was homozygous for the wild-
type allele.
In order to conﬁrm the pathogenicity of this mutation,
we used a retroviral vector20 to express the wild-type
cDNA for C12orf65 in ﬁbroblasts from patient 1, from
controls, and from a group of genetically uncharacterized
combined OXPHOS deﬁciency patients. Retroviral vectors
were created with the Gateway cloning system (Invitrogen)
as previously described,20 and the cDNA from theC12orf65
gene was ampliﬁed by OneStep RT-PCR (QIAGEN) with
speciﬁc primers. Retroviral constructs were used to tran-
siently transfect a Phoenix packaging cell line via the
HBS/Ca3(PO4)2 method (see Web Resources). Fibroblasts
were infected 48 hr later by exposure to virus-containing
medium in the presence of 4 mg/ml of polybrene.14
This approach enabled us to identify another, unrelated
patient with a mutation in C12orf65. Patient 2, a Leigh-like
patient, showed a virtually identical pattern of combined
OXPHOS deﬁciency as in patient 1 (Figure 1; Figure 2;The ACOX/citrate synthase activity of 40% of control). Expres-
sion of the wild-type C12orf65 cDNA rescued the mito-
chondrial protein synthesis defect in both patients
(Figure 1B), which resulted in near control levels of all OX-
PHOS complexes in patient ﬁbroblasts (Figure 1A). Overex-
pression of the mutated C12orf65, a protein with a stop
codon at position 84 (Figure 3), which still contains the
highly conserved class I release factor motif, did not rescue
the defect in ﬁbroblasts from patient 1; however, we do not
knowwhether this protein is expressed, because antibodies
against C12orf65 are not available. Sequence analysis of
patient 2 cDNA revealed a homozygous 1 bp deletion at
position 210 (210delA; Figure 3), which also resulted in
a premature stop codon at position 84 in C12orf65 protein,
as in patient 1. DNA from the parents of patient 2 was not
available for study. The level of the C12orf65 mRNA was
not signiﬁcantly reduced on RT-PCR in either patient, sug-
gesting that nonsense-mediated mRNA decay does not
contribute to the loss of function of the C12orf65 gene
product. Immunocytochemistry experiments with FLAG-
tagged versions of C12orf65 protein revealed that it local-
izes exclusively to mitochondria (Figure 3C).
The molecular defects produced by knockdown of Ict1
with Stealth (Invitrogen) RNAis were very similar to those
found in patients withC12orf65mutation (Figures 4A–4C);
however, expression of Ict1 from a retroviral vector failed
to rescue the biochemical defect in our bank of patientsmerican Journal of Human Genetics 87, 115–122, July 9, 2010 119
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Figure 5. Overexpression of Ict1, but Not mtRF1 or mtRF1a/
mtRF1L, Leads to a Partial Rescue of the OXPHOS Defect in
C12orf65 Patients
(A) BN-PAGE analysis of untreated control and patient ﬁbroblasts
and of those overexpressing C12orf65, Ict1, mtRF1, or mtRF1a/
mtRF1L (mtRF1a/L). Each of the ﬁve OXPHOS complexes (I–V)
was visualized with a subunit-speciﬁc antibody.
(B) Quantiﬁcation of COX activity (normalized to citrate synthase
activity and expressed as a percentage of control) in ﬁbroblasts
from the patients alone and overexpressing C12orf65, Ict1,
mtRF1, or mtRF1a/mtRF1L (3–9 replicates per sample).
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Figure 6. C12orf65 Does Not Have Detectable Peptidyl-tRNA
Hydrolase Activity in an In Vitro Assay with Bacterial Ribosomes
E. coli ribosomes were programmed with f[3H]-Met tRNAMet at the
P site and the indicated codons at the A site. Activity wasmeasured
as speciﬁc hydrolysis of f[3H]-Met from its cognate tRNAMet and
expressed as cpm released. mtRF1a/mtRF1L, which recognizes
the two mitochondrial termination codons UAA and UAG, was
used as a positive control.with combined OXPHOS deﬁciencies. Strikingly, no
defects in overall mitochondrial translation or the
assembly and function of the OXPHOS complexes were
observed after knockdown of mtRF1a/mtRF1L, the release
factor that is thought to be sufﬁcient to recognize both
stop codons.8
In order to investigate whether any of the members of
the RF1 family were able to suppress the defect found in
C12orf65 patients, we overexpressed the other three
members (mtRF1, mtRF1a/mtRF1L, and Ict1) in control
and patient ﬁbroblasts. The overexpression of these factors
in control cells did not have any effect on OXPHOS
biogenesis (Figure 5A); however, overexpression of Ict1,
but not mtRF1 or mtRF1a/mtRF1L, resulted in a partial
(50%) increase in COX activity over that in patient ﬁbro-120 The American Journal of Human Genetics 87, 115–122, July 9, 20blasts (Figure 5B). Correspondingly, the assembly of COX
was increased in patient ﬁbroblasts overexpressing Ict1,
as was the assembly of complexes I, V, and III
(Figure 5A), suggesting that C12orf65 and Ict1 have similar
and, to some extent, overlapping functions.
To test whether C12orf65, like Ict1, has codon-indepen-
dent peptidyl-tRNAhydrolase activity, we used a previously
described assay5,8 with E. coli 70S ribosomes (Figure 6).
GST-tagged proteins mtRF1a/mtRF1L and C12orf65 were
prepared with E. coli strain Rosetta(DE3)pLysS (Novagen),
puriﬁed and used in the in vitro translation termination
assay. Although the positive control, mtRF1a, showed
peptide release activity for the two termination codons
(UAA and UAG), with C12orf65 no peptidyl-tRNA hydro-
lase activity could be detected in the presence, or in the
absence, of any codon. We cannot rule out the possibility
that C12orf65 does, in fact, have such an activity but
that it requires 55S mitochondrial ribosomes or additional
factors or that it is ribosome independent. MtRF1 similarly
has no peptidyl-tRNA hydrolase activity when assayed on
bacterial ribosomes.8
What could be the role of C12orf65? The three-dimen-
sional (3D) structure of C12orf65, Ict1, mtRF1, and
mtRF1a/mtRF1L was modeled on the crystal structure of
the bacterial homolog RF26 with the I-TASSER server22–24
and was viewed with Swiss-MODEL by using the Swiss-
Pdb Viewer.25
In silico 3D structure modeling of the four mitochon-
drial class I peptide release factor proteins predicts prokary-
otic RF1 and RF2 as the best structure templates for the
entire family, with mtRF1a/mtRF1L having the highest10
C12orf65
Rf2 from E. coli
Ict1
mtRF1a/mtRF1L mtRF1
Rf2 from E. coli
Rf2 from E. coli Rf2 from E. coli
Figure 7. Molecular Modeling of Mitochondrial
Class I Release Factor Proteins
The best ﬁt for the predicted 3D structure of
C12orf65, Ict1, mtRF1, or mtRF1a/mtRF1L is the
crystal structure of translation release factor RF2
from E. coli (yellow). The red arrows indicate the
conserved class I release factor motif GGQ in domain
III. The yellow arrows indicate the domain II loop in
which the tripeptide motif (SPF in RF2) involved in
stop codon recognition is positioned.conﬁdence score and Ict1 the lowest (Figure 7). Compared
to RF2 from E. coli, C12orf 65 is missing domain 1, part of
domain 2 (up to the beta3 sheet), and the last two helices
of domain 4. Domain 1 interacts with the N-terminal
domain of the L11 ribosomal subunit, which is thought
to interact with translation factors.26 Immunoprecipita-
tion studies suggest that C12orf65 is a soluble matrix
protein that does not associate with the mitochondrial
ribosome,5 so it could perhaps play a role in processing
peptidyl-tRNAs that have been prematurely released
during polypeptide elongation. Accumulation of such pep-
tidyl-tRNAs would lead to depletion of aminoacylated
tRNAs, resulting in diminished protein synthesis. In
bacteria, recycling of these molecules is accomplished by
peptidyl-tRNA hydrolase (Pth), an esterase that cleaves
the ester bond between the C-terminal end of the peptide
and the 20- and 30-hydroxyl of the ribose at the end of the
tRNA.27 Two classes of Pth, which differ in substrate spec-
iﬁcity, have also been described in eukaryotes: Pth1, an
ortholog of the eubacterial enzymes, and Pth2, an ortholog
of the archeal enzymes. In Saccharomyces cerevisiae, dele-
tion of both of the Pth genes results in viable strains, but
with a retarded growth on nonfermentable carbon sources,
suggesting a role in mitochondrial translation.28 The
human ortholog of Pth2, also called Bcl-2 inhibitor of tran-
scription 1 (Bit1), is a mitochondrial protein with a bifunc-
tional activity. Bit1 possesses peptidyl-tRNA hydrolase
activity in vitro, and this has been presumed to be present
in mitochondria; but when released into the cytoplasm, it
promotes apoptosis.29 Although there are no apparent
similarities of C12orf65 to the Pth domains in these
proteins, this does not rule out the possibility that a class
I release factor might be necessary to process some abortive
translation intermediates.The American JournDespite the clear structural and functional
differences between C12orf65 and Ict1, over-
expression of Ict1 is capable of partially sup-
pressing the biochemical defect in C12orf65
patient cells. These data suggest that Ict1 and
C12orf65 have partially overlapping func-
tions. How might this occur? Previous experi-
ments have shown that a large fraction of
overexpressed Ict1 does not associate with
the mt-LSU, but rather accumulates in the
mitochondrial matrix.5 Although the pep-
tidyl-tRNA hydrolase activity of Ict1 in theabsence of E. coli ribosomes was shown to be negligible,5
it is possible that it maintains at least some activity in
mammalian mitochondria when soluble and that this
activity is enough to partially compensate for the loss of
C12orf65. Clearly, much further work will be required to
elucidate the speciﬁc function of C12orf65.Supplemental Data
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